UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

描述(由申请人提供)：北卡罗来纳大学教堂山分校(UNC)与杜克大学和哈姆纳药物安全科学研究所合作，为临床药理学的T32培训计划做好了准备。我们在临床药理学方面拥有出色的研究环境，在药物基因组学、药物发现、药物开发和药物安全方面拥有世界级的项目，在临床药理学方面培训临床医生和科学家的出色记录，以及优秀的申请者队伍。本申请中详细介绍的临床药理学培训计划提供了强大的领导力、积极参与临床药理学的来自多个学科的国际公认的导师、广泛的尖端技术和资源，以及具有强大机构支持的独特协作环境。该项目的国家申请者将主要来自医学专业培训项目中寻求临床药理学职业道路的医学博士。学员将在个性化指导团队的指导下，完成临床药理学课程并参与特定项目的活动，以获得当代临床药理学研究的所有方面的专业知识，从伦理学和药物基因组学到临床试验设计。教师导师是根据他们在临床药理学研究中至少四个重点领域之一的生产率来选择的，这四个重点领域构成了本培训计划的核心：药物处置和行动；药物基因组学；药物诱导的器官毒性；定量药理学和临床试验设计。这一培训计划的一个独特之处是有机会将重点放在临床药理学中未被研究的领域，特别是儿科和药物安全。我们潜在学员对临床药理学的浓厚兴趣，北卡罗来纳大学、杜克大学和哈姆纳-北卡罗来纳大学药物安全科学研究所对临床药理学研究资源的无与伦比的投资，以研究三角公园为代表的智力丰富的地区环境(其集中了与临床药理学相关的生物医学科学)，以及我们长期卓越的研究和培训基础设施，这些结合在一起，创造了一个无与伦比的临床药理学培训机会。 与公共卫生的相关性：人们对疾病的生物学基础和药物治疗的个体间差异的理解出现了爆炸性增长。这为治疗和最终治愈疾病的药物开发和个体化治疗提供了前所未有的机会。拟议的计划将培养出训练有素的临床药理学家，以领导利用这些巨大机遇的努力。

DESCRIPTION (provided by applicant): The University of North Carolina at Chapel Hill (UNC), in collaboration with Duke University and the Hamner Institute for Drug Safety Sciences, is well positioned for a T32 training program in clinical pharmacology. We have an outstanding research environment in clinical pharmacology with world-class programs in pharmacogenomics, drug discovery, drug development and drug safety, an outstanding track record of training clinician-scientists in clinical pharmacology, and an excellent applicant pool. The clinical pharmacology training program detailed in this application offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program will be derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology. Trainees, guided by individualized mentoring teams, will complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research, from ethics and pharmacogenomics to clinical trial design. Faculty mentors were chosen based on their productivity in clinical pharmacology research in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Pharmacogenomics; Drug-induced Organ Toxicity; Quantitative Pharmacology and Clinical Trial Design. A unique feature of this training program is the opportunity to focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our potential trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC, Duke University, and the Hamner-UNC Institute for Drug Safety Sciences, the intellectually-rich regional environment represented by Research Triangle Park with its concentration of biomedical sciences related to clinical pharmacology, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology. PUBLIC HEALTH RELEVANCE: There has been an explosion in understanding of the biology underlying disease and interindividual variation in response to pharmacotherapy. This has provided unprecedented opportunities in drug development and the individualization of therapy to treat and ultimately cure disease. The proposed program will produce clinical pharmacologists that will be well-trained to lead the effort to capitalize on these great opportunities.